Meeting
2023 ASCO Annual Meeting
Phase 2 multicenter trial of rucaparib and nivolumab as maintenance therapy following first-line platinum-based chemotherapy in patients with advanced biliary tract cancer (BTC): BilT-02.
Authors
Vaibhav Sahai
University of Michigan, Ann Arbor, MI
Vaibhav Sahai , Kent A. Griffith , Laura Williams Goff , Oxana V. Crysler , Thomas Enzler , Mark Zalupski
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer - Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT03639935
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 4113)
DOI
10.1200/JCO.2023.41.16_suppl.4113
Abstract #
4113
Poster Bd #
434
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
A multicenter phase II trial of rucaparib in combination with nivolumab as maintenance therapy for patients with advanced biliary tract cancer.
First Author: Vaibhav Sahai
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Prognostic effects of co-occurring TP53 and KRAS aberrations in patients with advanced biliary tract cancer.
First Author: Taro Shibuki
Poster
2023 ASCO Annual Meeting
Randomized phase 2 study of maintenance olaparib vs olaparib plus durvalumab for DNA damage repair (DDR) gene mutated unresectable or metastatic biliary tract cancer (BTC) with durable response to first-line platinum-based chemotherapy: OPTIMUM trial.
First Author: YunJung Kim
Poster
2020 ASCO Virtual Scientific Program
NOGGO Ov-42/MAMOC: Rucaparib maintenance after bevacizumab maintenance following carboplatin-based first line-chemotherapy in ovarian cancer patients.
First Author: Elena Ioana Braicu